2023, Chemotherapy and Vaccines - Pharmacy Technician Pulse

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

JULY 16, 2025

The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization Chemotherapy

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Pharmacy Times

JUNE 9, 2025

SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

JUNE 27, 2025

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Pharmacists are well positioned to perform drug interaction checks, counsel patients on adherence and administration, and coordinate supportive care, including prophylaxis for infections (eg, granulocyte colony-stimulating factor, vaccines).

FDA

FDA Compounding Pharmacies Immunization Chemotherapy

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

JUNE 9, 2025

Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. To ensure continuity of care, patients included had seen a primary care provider both in the year prior to and following their diagnosis.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

Pharmacy Times

AUGUST 8, 2025

2 In patients who had received prior platinum-based chemotherapy but had not been treated with a HER2-targeted TKI or antibody-drug conjugate (ADC; n = 71), the ORR was approximately 75% (95% CI, 63–83), with 58% of patients achieving a DOR of at least 6 months.

FDA

FDA Compounding Pharmacies Hospitals Immunization

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

JUNE 18, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.

Immunization

Immunization Compounding Pharmacies Hospitals Chemotherapy

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Pharmacy Times

AUGUST 13, 2025

Lamya Al-Saleh, PharmD, RPh, graduated with the PharmD Class of 2023 from Chapman University School of Pharmacy in Irvine, California. AE Profile In October 2023, the FDA approved a triplet-therapy regimen combining BV, Len, and R for use in the treatment of patients with otherwise unclassifiable R/R DLBCL who are not candidates for ASCT.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Immunization Compounding Compounding Pharmacies

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Pharmacy Times

JUNE 11, 2025

Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.

Specialty Pharmacies

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

JUNE 17, 2025

Results American Oncology Network (AON) Pharmacy collected data on waste and cost avoidance from February 2023 to September 2023. If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. During this time frame, the pharmacy documented 152 interventions.

Mail-Order Pharmacies

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

From 2003 to 2023, 943 drugs were approved through the 505(b)(2) pathway. As of January 1, 2023, CMS has begun issuing unique J-codes to 505(b)(2) drugs dating back to 2003. “In However, 505(b)(2) drugs have been available since the 1980s.

FDA

FDA Compounding Pharmacies Dosage Hospitals

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

JUNE 12, 2025

Darkow noted that, unlike a “typical” medication, biologics are larger, and for these reasons, products can encompass a wide range of types of forms, such as certain vaccines, blood products, monoclonal antibodies, cellular therapies, and insulin. Unlike other medications and treatments, they are not chemically synthesized.

Compounding Pharmacies

Compounding Pharmacies Immunization FDA Hospitals

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. Within a week, he developed severe neutropenia, gastrointestinal shutdown, and septic complications requiring admission to the intensive care unit.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Pharmacy Times

JULY 9, 2025

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy. months) and 6.4 months).

Immunization

Immunization Compounding Pharmacies FDA Chemotherapy

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Compounding

Compounding Compounding Pharmacies Patient Care Immunization

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents FDA Compounding Pharmacies Hospitals

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

JUNE 17, 2025

Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.

Dosage

Dosage Compounding Pharmacies Immunization Chemotherapy

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

JUNE 19, 2025

6 Chimeric antigen receptor (CAR) cell therapies ranked 10th with 795 candidates, holding steady from 2023. The approval of the first CRISPR-Cas9-based therapy in 2023 has accelerated efforts toward allogeneic, off-the-shelf CAR T products. 6 CAR T-cell therapies continue to dominate the genetically modified space.

Compounding

Compounding Compounding Pharmacies FDA Immunization

From Med Rec to AI: Pharmacists Expanding Their Role in Oncology Innovation

Pharmacy Times

JULY 23, 2025

So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. It frees up appointment slots for patients who need urgent care and helps streamline the process for new patients. Przespolewski : Pharmacists play a large role in managing drug shortages, especially those on the front lines.

Specialty Pharmacies

Specialty Pharmacies Hospitals Compounding Pharmacies Immunization

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.

Compounding Pharmacies

Compounding Pharmacies Immunization Hospitals Compounding

TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Pharmacy Times

AUGUST 13, 2025

Low- and intermediate-risk patients typically receive transurethral resection of bladder tumor with a single dose of perioperative intravesical chemotherapy. And it appears that having the chemotherapy released slowly over weeks rather than in just a few hours is a much more effective approach.”

Compounding Pharmacies

Compounding Pharmacies Compounding Immunization Chemotherapy

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

JUNE 27, 2025

Around late 2023, a friend was diagnosed with metastatic colorectal cancer at 46 years old. After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

JULY 4, 2025

How will RFK Jr’s American dream for vaccines play out? Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Future of Pharma - Looking Ahead to 2023 Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!

Chemotherapy

Chemotherapy Packaging Communication Hospitals

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

JUNE 11, 2025

Additionally, patients may have received prior chemotherapy for advanced disease. Updated October 30, 2023. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. Accessed June 11, 2025. ClinicalTrials.gov identifier: NCT04395677. Accessed June 11, 2025.

FDA

FDA Compounding Pharmacies Immunization Hospitals

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

JUNE 9, 2025

Updated March 20, 2023. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

JULY 1, 2025

How will RFK Jr’s American dream for vaccines play out? Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Notably, priorities have shifted since 2023 in favour of greater competitiveness, he adds. Sign up for our daily news round-up!

Packaging

Packaging Chemotherapy Communication Hospitals

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Pharmacy Times

JUNE 18, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.

FDA

FDA Compounding Pharmacies Compounding Immunization

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

Pharmacy Times

AUGUST 7, 2025

Methods Patients aged 18 to 59 years with t-AML or AML-MRC treated with CPX-351 or 7+3 as induction chemotherapy between 2015 and 2022 at 3 National Cancer Institute–designated cancer centers were included. Study Design Retrospective, multicenter, observational cohort study.

Chemotherapy

Chemotherapy FDA Hospitals Immunization

Reinventing Transplant Care: From Inpatient Tradition to Outpatient Innovation

Pharmacy Times

JULY 3, 2025

I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.

Specialty Pharmacies

Specialty Pharmacies Compounding Pharmacies Hospitals Immunization

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Pharmacy Times

AUGUST 12, 2025

Usual treatments like chemotherapy, hormone therapy, radiation, and surgery have undeniably helped patients live longer. SHOW MORE Natural compounds like prunus armeniaca and bee venom enhance breast cancer treatment, boosting efficacy and reducing side effects. Yet, these come with substantial adverse effects and, often, therapy resistance.

Compounding

Compounding Compounding Pharmacies Immunization Vaccines

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy

Chemotherapy Compounding Pharmacies Hospitals Immunization

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Pharmaceutical Technology

JULY 4, 2025

How will RFK Jr’s American dream for vaccines play out? Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. Sign up for our daily news round-up!

Chemotherapy

Chemotherapy Packaging Communication Hospitals

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Pharmacy Times

JUNE 25, 2025

1 Scientific evidence between January 1, 2016, and January 31, 2023, was included in the study. This was assessed by analyzing real-world pharmacoepidemiological data and conducting a systematic review and meta-analysis to further quantify this risk. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Pharmacy Times

JUNE 18, 2025

PTCy recipients included those who received peripheral blood stem cells of haploidentical-related and mismatched unrelated donor transplants.

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Pharmacy Times

JUNE 6, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

J&J eyes prostate cancer label expansion for Akeega

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out? Akeega has been approved in Europe for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with steroid hormone prednisolone since 2023. Go deeper with GlobalData Reports LOA and PTSR Model - (Abiraterone Acetate + Niraparib) in Metastati.

Labelling

Labelling Packaging Communication Hospitals

Study: Prevalence and Clinical Implications of MASLD in Type 2 Diabetes

Pharmacy Times

JUNE 17, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 23, 2025

Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

FDA

FDA Compounding Pharmacies Chemotherapy Immunization

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Trending Sources

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

Pharmacies Need Strategies to Improve Health Care Access

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

From Med Rec to AI: Pharmacists Expanding Their Role in Oncology Innovation

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Big pharma braces for revenue headwinds as patent expiries loom

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacists Take the Lead on Advanced Therapeutics

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

Reinventing Transplant Care: From Inpatient Tradition to Outpatient Innovation

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

J&J eyes prostate cancer label expansion for Akeega

Study: Prevalence and Clinical Implications of MASLD in Type 2 Diabetes

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Stay Connected